BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia
Follicular Lymphoma
Acute Myelogenous Leukemia
Diffuse Large B-Cell Leukemia

Interventions: Drug: BMS-936564 (Anti-CXCR4)

First Posted Date: 2010-05-11

Last Posted Date: 2015-03-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 96

Registration Number: NCT01120457

Locations: 🇺🇸
Ucla-Division Of Hematology/Oncology, Los Angeles, California, United States
🇺🇸
The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Uc San Diego Moores Cancer Center, La Jolla, California, United States

and more 8 locations

Safety Study of BMS-823778 in Subjects With Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: BMS-823778
Drug: Placebo
Drug: Metformin

First Posted Date: 2010-04-28

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 62

Registration Number: NCT01111955

Locations: 🇺🇸
Capital Clinical Reserch Center, Olympia, Washington, United States
🇺🇸
Farid Marquez, Md, Hialeah, Florida, United States
🇨🇦
Local Institution, Quebec, Canada

and more 1 locations

Safety Study of BMS-823778 in Subjects With Hypercholesterolemia

Phase 2

Completed

Conditions: Dyslipidemia

Interventions: Drug: BMS-823778
Drug: Placebo

First Posted Date: 2010-04-28

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 60

Registration Number: NCT01112423

Locations: 🇺🇸
Pra International, Lenexa, Kansas, United States
🇺🇸
Sterling Research Grp, Ltd., Cincinnati, Ohio, United States
🇺🇸
Osborne Research Center, Little Rock, Arkansas, United States

and more 4 locations

Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment

Phase 3

Terminated

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Brivanib
Drug: Placebo

First Posted Date: 2010-04-22

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 87

Registration Number: NCT01108705

Locations: 🇨🇳
Local Institution, Taoyuan, Taiwan

Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Non-Insulin-Dependent

Interventions: Drug: BMS-820132
Drug: Placebo

First Posted Date: 2010-04-16

Last Posted Date: 2011-03-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 56

Registration Number: NCT01105429

Locations: 🇺🇸
Profil Institute For Clinical Research, Inc. (Picr), Chula Vista, California, United States
🇺🇸
Elite Research Institute, Miami, Florida, United States
🇺🇸
Clinical Pharmacology Of Miami Inc., Miami, Florida, United States

PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Atazanavir powder
Drug: Ritonavir oral solution
Drug: Atazanavir capsules
Drug: Ritonavir capsules

First Posted Date: 2010-04-07

Last Posted Date: 2018-05-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 82

Registration Number: NCT01099579

Locations: 🇹🇭
Local Institution, Bangkok, Thailand

A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure

Phase 2

Completed

Conditions: Heart Failure

Interventions: Drug: Strata 1 CXL-1020
Drug: Strata 3 CXL-1020
Drug: Strata 2 CXL-1020
Drug: Placebo

First Posted Date: 2010-03-30

Last Posted Date: 2016-11-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 69

Registration Number: NCT01096043

Locations: 🇺🇸
University of Florida, Jacksonville, Florida, United States
🇺🇸
Florida Hospital Transplant Center, Orlando, Florida, United States
🇺🇸
Henry Ford Health System, Detroit, Michigan, United States

and more 11 locations

Safety Study of Abatacept in Sweden

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2010-03-29

Last Posted Date: 2022-06-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 92635

Registration Number: NCT01094795

Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure

Phase 1

Completed

Conditions: Heart Failure

Interventions: Drug: CXL-1020
Drug: CXL-1020 Doses for Echo Cohort B
Drug: Placebo for CXL-1020 Cohort 1
Drug: Placebo for CXL-1020 Cohort 2
Drug: CXL-1020 Dose for Echo Cohort A

First Posted Date: 2010-03-24

Last Posted Date: 2016-07-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 28

Registration Number: NCT01092325

Locations: 🇺🇸
Orange County Clinical Research Center, Tustin, California, United States

Safety Study of Abatacept to Treat Rheumatoid Arthritis (B)

Active, not recruiting

Conditions: Rheumatoid Arthritis

First Posted Date: 2010-03-17

Last Posted Date: 2019-01-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 20000

Registration Number: NCT01088360

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy